Company Description
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.
Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma.
Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform.
Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Country | Israel |
Founded | 2000 |
IPO Date | Mar 13, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | Allen Baharaff |
Contact Details
Address: 16 Abba Hillel Road Ramat Gan, 5250608 Israel | |
Phone | 972 3 693 8448 |
Website | galmedpharma.com |
Stock Details
Ticker Symbol | GLMD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001595353 |
CUSIP Number | M47238106 |
ISIN Number | IL0011313900 |
Employer ID | 98-1147233 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Allen Baharaff | Co-Founder, President, Chief Executive Officer and Chairman |
Doron Cohen | Chief Financial Officer |
Guy Nehemya | Chief Operating Officer and Data Protection Officer |
Yohai Stenzler CPA | Chief Accounting Officer |
Dr. Liat Hayardeny MBA, Ph.D. | Chief Scientific Officer |
Dr. Tali Gorfine | Medical Consultant |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | 6-K | Report of foreign issuer |
Nov 14, 2024 | F-3 | Filing |
Nov 14, 2024 | 6-K | Report of foreign issuer |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 28, 2024 | EFFECT | Notice of Effectiveness |
Oct 28, 2024 | 424B3 | Prospectus |
Oct 21, 2024 | F-1 | Registration statement for certain foreign private issuers |
Oct 21, 2024 | 6-K | Report of foreign issuer |
Oct 15, 2024 | 6-K | Report of foreign issuer |
Sep 25, 2024 | 6-K | Report of foreign issuer |